Eltrombopag (ELT) is a first generation Thrombopoietin receptor (TPO-R) agonist, approved for the treatment of chronic idiopathic thrombocytopenia (ITP) and thrombocytopenia associated with chronic hepatitis C (HCV) in both pediatric and adult patients [14, 15]. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.